For those with ALS, specialized computers a godsend

Richmond Times-Dispatch - 4 days ago
“CMS extended this review until...

Agnico Eagle's Amaruq project (formerly "IVR") near Meadowbank yields ...

PR Newswire (press release) - 2 days ago
"Drilling at Amaruq continues...

BlackBerry CEO: 200000 Passports ordered since launch

CNET - 5 days ago
The unusually shaped smartphone...

Pearls Before Breakfast: Can one of the nation's great musicians cut through ...

Washington Post - 1 week ago
Called the Gibson ex Huberman, it...

Icons to Our Area Part 1

Daily Journal Online - 1 week ago
Editor's Note: For 60 days,...

COMPUTER BILD-Netztest: ZTE-Kunde E-Plus auf Platz zwei

SYS-CON Media (press release) - 2 days ago
E-Plus und ZTE vereinbarten im...

No septic, no loan: Phoenicia Pharmacy sale falls through

Woodstock Times - 2 weeks ago
Both Ullman and the previous...

Medicare statement on ALS speech-generating devices

Washington Post - 4 weeks ago
A spokesman for the Centers for...

HEVC-Patentportfolio als Lizenzangebot von MPEG LA

SYS-CON Media (press release) - 2 days ago
Das Lizenzpaket enthält...

Geomega Resources Inc.: Gold-Bearing Corridor on Anik Increases to 600 Meters

SYS-CON Media (press release) - 2 days ago
All samples have been assayed at...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.